Sibrowski W, Brauer P
Institut für Transfusionsmedizin, Westfälischen Wilhelms-Universität, Münster.
Infusionsther Transfusionsmed. 1994 Nov;21 Suppl 3:19-22.
New developments concerning the diagnostic of virus-transmitted diseases led to a strong improvement of virus security in hemotherapy. The introduction of additional virus antigens associated with the core region of the hepatitis C virus (HCV) resulted in an increase of sensitivity and especially of specificity of second-generation enzyme immuno assays (EIAs). The recombinant immunoblot (RIBA) with 4 synthetic antigens continues to be the most accepted confirmatory test in the field of HCV diagnostic. Beside the simultaneous detection of specific IgG and IgM, especially the HIV-p24 antigen test is discussed concerning HIV-1, -2 diagnostic in order to shorten the 'windows period' in the early time of infection. It is assumed that the HIV-p24 antigen test is not able to effectively improve virus security in areas with low HIV-1, -2 prevalence.
病毒传播性疾病诊断方面的新进展极大地提高了血液疗法中的病毒安全性。与丙型肝炎病毒(HCV)核心区域相关的额外病毒抗原的引入,提高了第二代酶免疫测定(EIA)的灵敏度,尤其是特异性。含有4种合成抗原的重组免疫印迹法(RIBA)仍是HCV诊断领域最被认可的确认性检测方法。除了同时检测特异性IgG和IgM外,尤其讨论了HIV-p24抗原检测在HIV-1、-2诊断中的应用,以缩短感染早期的“窗口期”。据推测,HIV-p24抗原检测在HIV-1、-2低流行地区无法有效提高病毒安全性。